Viracta Therapeutics Inc 's (VIRX) Outlook - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 
Viracta Therapeutics Inc   (NASDAQ: VIRX)
 



  Viracta Therapeutics Inc Outlook

On March 7 2024 the Viracta Therapeutics Inc provided following guidance

Viracta Therapeutics Inc. released its financial results for the fourth quarter and full year of 2023, along with an update on its business operations. The company successfully completed Stage 2 enrollment in the NAVAL-1 trial of Nana-val, a treatment for patients with relapsed or refractory EBV peripheral T-cell lymphoma. This development is in line with the company's strategy to bring new treatments to market quickly.

The topline results from Stage 1 of the NAVAL-1 trial are expected to be reported in the second quarter of 2024. This milestone represents an important step forward in Viracta Therapeutics' efforts to address unmet medical needs in the field of cancer treatment. The company remains committed to advancing innovative therapies that have the potential to improve outcomes for patients with difficult-to-treat cancers.

Overall, Viracta Therapeutics continues to make progress in its research and development efforts, with a focus on bringing promising treatments to market. The company's dedication to advancing novel therapies for patients in need underscores its commitment to making a meaningful impact in the fight against cancer.





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.